These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11749394)

  • 1. Comparative QSAR: angiotensin II antagonists.
    Kurup A; Garg R; Carini DJ; Hansch C
    Chem Rev; 2001 Sep; 101(9):2727-50. PubMed ID: 11749394
    [No Abstract]   [Full Text] [Related]  

  • 2. How to design a potent, specific, and stable angiotensin-converting enzyme inhibitor.
    Regulska K; Stanisz B; Regulski M; Murias M
    Drug Discov Today; 2014 Nov; 19(11):1731-1743. PubMed ID: 24997281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probing the importance of spacial and conformational domains in captopril analogs for angiotensin converting enzyme activity.
    Hanessian S; Reinhold U; Saulnier M; Claridge S
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2123-8. PubMed ID: 9873498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paramagnetic bradykinin analogues as substrates for angiotensin I-converting enzyme: Pharmacological and conformation studies.
    Teixeira LG; Malavolta L; Bersanetti PA; Schreier S; Carmona AK; Nakaie CR
    Bioorg Chem; 2016 Dec; 69():159-166. PubMed ID: 27837711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors.
    Nchinda AT; Chibale K; Redelinghuys P; Sturrock ED
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4612-5. PubMed ID: 16784850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on the Bioactivities of ACE-inhibitory Peptides with Phenylalanine C-terminus Using 3D-QSAR, Molecular Docking and in vitro Evaluation.
    Qi C; Lin G; Zhang R; Wu W
    Mol Inform; 2017 Sep; 36(9):. PubMed ID: 28452129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of human angiotensin converting enzyme by copper peptide complexes containing ATCUN motifs.
    Gokhale NH; Cowan JA
    Chem Commun (Camb); 2005 Dec; (47):5916-8. PubMed ID: 16317474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.
    Jullien N; Makritis A; Georgiadis D; Beau F; Yiotakis A; Dive V
    J Med Chem; 2010 Jan; 53(1):208-20. PubMed ID: 19899765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative structure (inhibitory) activity relationship and molecular docking studies of phenolic acids to angiotensin-converting enzyme.
    Gonzales GB; Van Camp J; Al Shukor N; Staljanssens D; Struijs K; Zotti M; Raes K; Smagghe G
    Commun Agric Appl Biol Sci; 2014; 79(1):41-4. PubMed ID: 25864311
    [No Abstract]   [Full Text] [Related]  

  • 10. Classification-based QSAR Models for the Prediction of the Bioactivity of ACE-inhibitor Peptides.
    Tripaldi P; Pérez-González A; Rojas C; Radax J; Ballabio D; Todeschini R
    Protein Pept Lett; 2018; 25(11):1015-1023. PubMed ID: 30430931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Vaccinium ashei reade leaves on angiotensin converting enzyme activity in vitro and on systolic blood pressure of spontaneously hypertensive rats in vivo.
    Sakaida H; Nagao K; Higa K; Shirouchi B; Inoue N; Hidaka F; Kai T; Yanagita T
    Biosci Biotechnol Biochem; 2007 Sep; 71(9):2335-7. PubMed ID: 17827680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perindopril and ramipril phosphonate analogues as a new class of angiotensin converting enzyme inhibitors.
    Gomez C; Berteina-Raboin S; De Nanteuil G; Guillaumet G
    Bioorg Med Chem; 2013 Nov; 21(22):7216-21. PubMed ID: 24095015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An ACE structure.
    Hooper NM; Turner AJ
    Nat Struct Biol; 2003 Mar; 10(3):155-7. PubMed ID: 12605218
    [No Abstract]   [Full Text] [Related]  

  • 14. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
    Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
    J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiotensin converting enzyme-angiotensin II system, atherosclerosis, and angiotensin-converting enzyme inhibitors].
    Aronov DM
    Ter Arkh; 2000; 72(12):5-7. PubMed ID: 11201833
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of new peptide inhibitors on the ratio of angiotensin I-converting and kinin-degrading activities of dipeptidyl carboxypeptidase (angiotensin-converting enzyme).
    Kalinina EV; Posdnev VF; Komissarova NV; Gomazkov OA
    Biochemistry (Mosc); 1997 Mar; 62(3):247-50. PubMed ID: 9275297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico identification of milk antihypertensive di- and tripeptides involved in angiotensin I-converting enzyme inhibitory activity.
    Vukic VR; Vukic DV; Milanovic SD; Ilicic MD; Kanuric KG; Johnson MS
    Nutr Res; 2017 Oct; 46():22-30. PubMed ID: 29173648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demonstration of extrapulmonary activity of angiotensin converting enzyme in intact tissue preparations.
    Lembeck F; Griesbacher T; Eckhardt M
    Br J Pharmacol; 1990 May; 100(1):49-54. PubMed ID: 2164861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kaempferol, but not resveratrol inhibits angiotensin converting enzyme.
    Olszanecki R; Bujak-Gizycka B; Madej J; Suski M; Wołkow PP; Jawień J; Korbut R
    J Physiol Pharmacol; 2008 Jun; 59(2):387-92. PubMed ID: 18622053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refinement of Catalyst hypotheses using simplex optimisation.
    Norinder U
    J Comput Aided Mol Des; 2000 Aug; 14(6):545-57. PubMed ID: 10921771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.